Literature DB >> 20551914

In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration.

Oleg S Gorbatyuk1, Shoudong Li, Kevin Nash, Marina Gorbatyuk, Alfred S Lewin, Layla F Sullivan, Ronald J Mandel, Weijun Chen, Craig Meyers, Fredric P Manfredsson, Nicholas Muzyczka.   

Abstract

Two small-interfering RNAs (siRNAs) targeting alpha-synuclein (alpha-syn) and three control siRNAs were cloned in an adeno-associated virus (AAV) vector and unilaterally injected into rat substantia nigra pars compacta (SNc). Reduction of alpha-syn resulted in a rapid (4 week) reduction in the number of tyrosine hydroxylase (TH) positive cells and striatal dopamine (DA) on the injected side. The level of neurodegeneration induced by the different siRNAs correlated with their ability to downregulate alpha-syn protein and mRNA in tissue culture and in vivo. Examination of various SNc neuronal markers indicated that neurodegeneration was due to cell loss and not just downregulation of DA synthesis. Reduction of alpha-syn also resulted in a pronounced amphetamine induced behavioral asymmetry consistent with the level of neurodegeneration. In contrast, none of the three control siRNAs, which targeted genes not normally expressed in SNc, showed evidence of neurodegeneration or behavioral asymmetry, even at longer survival times. Moreover, co-expression of both rat alpha-syn and alpha-syn siRNA partially reversed the neurodegenerative and behavioral effects of alpha-syn siRNA alone. Our data show that alpha-syn plays an important role in the rat SNc and suggest that both up- and downregulation of wild-type alpha-syn expression increase the risk of nigrostriatal pathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551914      PMCID: PMC2927065          DOI: 10.1038/mt.2010.115

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  30 in total

1.  Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.

Authors:  Masanori Yamada; Takeshi Iwatsubo; Yoshikuni Mizuno; Hideki Mochizuki
Journal:  J Neurochem       Date:  2004-10       Impact factor: 5.372

2.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

3.  Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody.

Authors:  S Yu; X Li; G Liu; J Han; C Zhang; Y Li; S Xu; C Liu; Y Gao; H Yang; K Uéda; P Chan
Journal:  Neuroscience       Date:  2007-02-01       Impact factor: 3.590

4.  Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.

Authors:  Andisheh Eslamboli; Marina Romero-Ramos; Corinna Burger; Tomas Bjorklund; Nicholas Muzyczka; Ronald J Mandel; Harry Baker; Rosalind M Ridley; Deniz Kirik
Journal:  Brain       Date:  2007-02-15       Impact factor: 13.501

5.  A role for alpha-synuclein in the regulation of dopamine biosynthesis.

Authors:  Ruth G Perez; Jack C Waymire; Eva Lin; Jen J Liu; Fengli Guo; Michael J Zigmond
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

6.  Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.

Authors:  Xiangmin Peng; Xiangmin M Peng; Roya Tehranian; Paula Dietrich; Leonidas Stefanis; Ruth G Perez
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

7.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

Review 8.  Cell systems and the toxic mechanism(s) of alpha-synuclein.

Authors:  Mark R Cookson; Marcel van der Brug
Journal:  Exp Neurol       Date:  2007-06-04       Impact factor: 5.330

9.  Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.

Authors:  Abdelmojib Al-Wandi; Natalia Ninkina; Steven Millership; Sally J M Williamson; Paul A Jones; Vladimir L Buchman
Journal:  Neurobiol Aging       Date:  2008-12-20       Impact factor: 4.673

10.  Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells.

Authors:  Dongmei Liu; Ling Jin; Hao Wang; Huanying Zhao; Chunli Zhao; Chunli Duan; Lingling Lu; Bo Wu; Shun Yu; Piu Chan; Yaohua Li; Hui Yang
Journal:  Neurochem Res       Date:  2008-03-21       Impact factor: 3.996

View more
  94 in total

Review 1.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 2.  Gene-based therapies in Parkinson's disease.

Authors:  Patricia J Allen; Andrew Feigin
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Gene therapy targeting mitochondrial pathway in Parkinson's disease.

Authors:  Chi-Jing Choong; Hideki Mochizuki
Journal:  J Neural Transm (Vienna)       Date:  2016-09-16       Impact factor: 3.575

Review 4.  Genetic therapy for the nervous system.

Authors:  William J Bowers; Xandra O Breakefield; Miguel Sena-Esteves
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

Review 5.  RNAi medicine for the brain: progresses and challenges.

Authors:  Ryan L Boudreau; Edgardo Rodríguez-Lebrón; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2011-03-31       Impact factor: 6.150

6.  Production and discovery of novel recombinant adeno-associated viral vectors.

Authors:  Christian Mueller; Dmitry Ratner; Li Zhong; Miguel Esteves-Sena; Guangping Gao
Journal:  Curr Protoc Microbiol       Date:  2012-08

7.  An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.

Authors:  Christina E Khodr; Mohan K Sapru; Jyothi Pedapati; Ye Han; Neva C West; Adrian P Kells; Krystof S Bankiewicz; Martha C Bohn
Journal:  Brain Res       Date:  2011-04-22       Impact factor: 3.252

Review 8.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

9.  Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Jeffrey H Kordower; Pedro Gonzalez-Alegre; Beverly L Davidson
Journal:  Brain       Date:  2015-10-21       Impact factor: 13.501

10.  Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.

Authors:  Alison L McCormack; Sally K Mak; Jaimie M Henderson; David Bumcrot; Matthew J Farrer; Donato A Di Monte
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.